Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice the first effects of Wegovy within the initial one to two weeks, though meaningful weight loss typically builds across several months. Semaglutide, the active ingredient, begins reducing appetite almost immediately after the first dose — but the scale responds more slowly. Clinical trials published in the New England Journal of Medicine (STEP 1) found that adults using semaglutide 2.4mg lost an average of around 15% of body weight over 68 weeks. That timeline matters: Wegovy is a long-acting weekly injection, not a quick fix, and results accumulate progressively as the dose is titrated and the body adapts. As a prescription-only medicine, it is only available following clinical assessment by a registered prescriber who judges whether it is appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starter dose is 0.25mg, and its job is adjustment, not weight loss. Your body is learning to work with a new signal. Appetite can dip noticeably even at this stage, some people find meals feel smaller, snacking drops off, and hunger arrives later in the day. The scale may barely shift, or not at all. That is expected.
Side effects are most likely to show up now: nausea, occasional vomiting, loose stools or constipation. They cluster around the time of each injection and usually settle within a few days. Staying hydrated and eating smaller, lower-fat meals helps most people through this phase. If you want to understand how the general semaglutide timeline for weight loss compares across injection and tablet forms, that page covers the broader picture.
Your prescriber, not you, decides when and whether to move to the next dose level. At a minimum, four weeks pass at each rung before any increase.
Doses step up through 0.5mg, then 1.0mg, then 1.7mg on a roughly monthly schedule managed by your prescriber. This is when most people see the scale responding in a way that feels real. Appetite suppression deepens. Food noise (the constant low-level thinking about eating) often quietens substantially, which many patients say surprises them more than the weight change itself.
By the end of month three, a loss of around 5 to 8% of starting body weight is broadly consistent with trial data, though the range is wide. If you are curious about how long Wegovy takes to work for weight loss, that page breaks down the evidence across the full treatment timeline in more detail. Factors including starting BMI, physical activity and any weight-related conditions affect the pace.
The second-month results page goes into more detail on what the evidence shows at this specific point in treatment. The key practical point is that dose titration is non-negotiable, rushing it increases the risk of side effects without improving outcomes.
Reaching 2.4mg weekly is the standard clinical endpoint for most people on the original Wegovy pathway. From here, weight loss continues but the pace gradually slows as the body approaches a new equilibrium. The largest and most sustained losses come to people who keep the dose steady, maintain lifestyle changes and stay under regular clinical review.
The MHRA approved a higher 7.2mg maintenance dose in January 2026, and a dedicated single-dose pen for it followed in April 2026. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide. Not everyone will reach 7.2mg; clinical assessment determines the right endpoint. For a fuller overview of the treatment, the Wegovy treatment page covers licensing, eligibility and what the prescription process involves.
NICE guidance on semaglutide (published as TA875) recommends continuing treatment only while it is producing meaningful results. If weight loss falls below 5% after six months at the maintenance dose, continuing should be reviewed with a prescriber. That review point is not a failure, it is the system working as intended.
Speed of response is genuinely individual. Starting BMI plays a role: people with a higher starting point tend to see larger absolute losses in the early months, though percentage changes vary. If you want a detailed look at how quickly Wegovy works for weight loss, that page examines the factors that shape individual response in depth. Strength or resistance activity helps preserve lean mass during rapid weight loss, which matters for long-term metabolic health.
Medical history matters too. Certain medicines interact with semaglutide. Oral contraceptives may be affected because GLP-1 treatment slows gastric emptying, and the NHS England guidance on weight management injections covers specific advice around contraception and HRT for people starting this treatment.
Practical consistency also adds up. Wegovy is injected once weekly, same day each week, rotating between the abdomen, thigh and upper arm. Missing doses or inconsistent timing disrupts the steady-state levels that make the medicine effective, and reading about how fast Wegovy works can help set realistic expectations around what consistent dosing actually delivers. Your pen arrives in plain, unbranded packaging (tracked by DPD) so there is nothing that draws attention; consistency is down to building a weekly habit rather than chasing a delivery.
If you are considering starting treatment or want to understand whether Wegovy is the right fit given your timeline expectations, exploring weight-loss treatment options is a sensible first step, or you can check the general FAQs for common questions about the process.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.